Comparative Pharmacology
Head-to-head clinical analysis: MYHIBBIN versus VFEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYHIBBIN versus VFEND.
MYHIBBIN vs VFEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
IV: Loading dose of 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours. Oral: Weight ≥40 kg: Loading dose of 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours; weight <40 kg: Loading dose of 200 mg every 12 hours for 2 doses, then 100 mg every 12 hours.
None Documented
None Documented
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Terminal half-life is approximately 24 hours (range 12–30 h) in adults. Prolonged in hepatic impairment (Child-Pugh A: 48 h; B: 72 h).
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Primarily hepatic metabolism; <2% excreted unchanged in urine. Fecal excretion accounts for ~80% of metabolites. Renal excretion of unchanged drug is negligible.
Category C
Category C
Antifungal
Antifungal